A phase II clinical trial of celecoxib combined with platinum-based regimen as first-line chemotherapy for advanced non-small cell lung cancer patients with cyclooxygenase-2 positive expression
作者： Jun Zhao , Zhi-jie Wang , Jian-chun Duan , Qing-zhi Guo , Hua Bai
DOI: 10.1007/S11670-009-0001-3
关键词: First line chemotherapy 、 Cyclooxygenase 、 Clinical trial 、 Medicine 、 Non small cell 、 Lung cancer 、 Internal medicine 、 Celecoxib 、 Regimen 、 Chemotherapy 、 Surgery 、 Oncology
摘要: Objective To evaluate the efficacy and safety of celecoxib plus platinum-doublet as first-line chemotherapy in treatment advanced non-small cell lung cancer (NSCLC), to determine subgroup benefiting from combined therapy by molecular analysis.
springer.com
core.ac.uk 
sci-hub.se 参考文章(41)
Dennis J. Slamon, Brian Leyland-Jones, Steven Shak, Hank Fuchs, Virginia Paton, Alex Bajamonde, Thomas Fleming, Wolfgang Eiermann, Janet Wolter, Mark Pegram, Jose Baselga, Larry Norton, Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 The New England Journal of Medicine. ,vol. 344, pp. 783- 792 ,(2001) , 10.1056/NEJM200103153441101
LV Mei-jun, First-line regimen of Vinorelbine and Cisplatin(NP) combined with cyclooxygenase-2 inhibitor celecoxib in advanced non-small-cell lung cancer Journal of Tongji University. ,(2007)
Sabine Zöchbauer-Müller, Adi F. Gazdar, John D. Minna, Molecular pathogenesis of lung cancer. Annual Review of Physiology. ,vol. 64, pp. 681- 708 ,(2002) , 10.1146/ANNUREV.PHYSIOL.64.081501.155828
J Oan H. S Chiller, C Handra P. B Elani, J Ames K Rook, C Orey L Anger, J Unming Z Hu, D Avid H. J Ohnson, D Avid H Arrington, A Lan S Andler, COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER ,(2002)
Fadlo R. Khuri, Reuben Lotan, Bonnie L. Kemp, Lei Feng, Xiao-Chun Xu, Scott M. Lippman, J. Jack Lee, Waun K. Hong, Hong Wu, Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clinical Cancer Research. ,vol. 7, pp. 861- 867 ,(2001)
Frank V. Fossella, Russell DeVore, Ronald N. Kerr, Jeffrey Crawford, Ronald R. Natale, Frank Dunphy, Leonard Kalman, Vincent Miller, Jin Soo Lee, Melvin Moore, David Gandara, Daniel Karp, Everett Vokes, Mark Kris, Yong Kim, Francis Gamza, Luz Hammershaimb, , Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens Journal of Clinical Oncology. ,vol. 18, pp. 2354- 2362 ,(2000) , 10.1200/JCO.2000.18.12.2354
Paul A. Bunn, Karen Kelly, New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clinical Cancer Research. ,vol. 4, pp. 1087- 1100 ,(1998)
Yoon Kyung Jeon, Sook-Whan Sung, Jin-Haeng Chung, Weon-Seo Park, Jeong-Wook Seo, Chul Woo Kim, Doo Hyun Chung, Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer Lung Cancer. ,vol. 54, pp. 387- 398 ,(2006) , 10.1016/J.LUNGCAN.2006.08.015
M Parrett, R Harris, F Joarder, M Ross, K Clausen, F Robertson, Cyclooxygenase-2 gene expression in human breast cancer. International Journal of Oncology. ,vol. 10, pp. 503- 507 ,(1997) , 10.3892/IJO.10.3.503
J.Esteban Castelao, Robert D Bart, Costanzo A DiPerna, Eric M Sievers, Ross M Bremner, Lung cancer and cyclooxygenase-2 The Annals of Thoracic Surgery. ,vol. 76, pp. 1327- 1335 ,(2003) , 10.1016/S0003-4975(03)00334-5